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Abstract The 5-hydroxytryptamine (5-HT) has been
implicated in migraine pathophysiology for the past
50 years. A low central 5-HT disposition associated with
an increase in 5-HT release during attack is the most
convincing change of 5-HT metabolism implicated in
migraine. Peripheral studies on plasma/platelet have not
generally shown low 5-HT levels. Studies on 5-HT reac-
tivity showed hypersensitivity, also expressed as reduced
tachyphylaxis (habituation), which successively was evi-
denced as the most characteristic marker of an altered
sensory neurotransmission. Even the gender and seasonal
variations of 5-HT parameters seem to agree with a low 5-
HT turnover with receptoral hypersensitivity. The inter-
pretation of the effects of some serotonergic drugs and
recent neuroimaging studies give major evidence for this
cascade of events. Although the exact mechanism that links
abnormal 5-HT neurotransmission to the manifestation of
head pain has yet to be fully understood, a deficit on 5-HT
descending pain inhibitory system is still probably today
the most implicated in migraine pathophysiology. This
short review focuses and discusses the alteration of
peripheral and central 5-HT parameters in migraine
patients.
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Introduction
Thirteen years ago, concluding a revision on studies con-
cerning the alterations of peripheral (platelets, vessels)
serotonergic parameters in migraine patients I stated,
‘‘Why conduct any more research in the periphery?’’ [1]. In
fact, further studies in plasma/platelet do not yield sub-
stantial new findings, while other vascular studies were not
performed.
Since the first evidence from the Florence researchers
of an altered metabolism of 5-hydroxytryptamine (5-HT),
that is an increased urinary excretion of the 5-HT
metabolite 5-hydroxyndoleacetic acid (5-HIAA) [2], the
aim of studies on 5-HT was to show if migraine subjects
have others modifications of 5-HT parameters. The ori-
ginal hypothesis of a deficiency of central 5-HT
neurotransmission (empty neuron) as a biological marker
of migraine subjects, with consequent 5-HT receptoral
hypersensitivity [3, 4] is today discussed. In this light, the
concept of 5-HT vulnerability, defined as increased sen-
sitivity to natural or experimental alterations of the
serotonergic system, proposed for depression [5] can be
valid also for migraine.
Other than peripheral studies (platelets/vessels), the
action of drugs affecting 5-HT central neurotransmission,
that is, 5-HT selective reuptake inhibitors (SRRI), 5-HT
releasers, 5-HT precursors, 5-HT receptor agonists, in
migraine subjects was evaluated [6]. More recently, studies
on possible genetic basis for altered 5-HT neurotransmis-
sion and neuroimaging studies on 5-HT metabolism were
performed [7, 8].
The aim of this review is to critically evaluate studies
concerning variations of 5-HT parameters, to try to define
some data in order to avoid that further research is based on
incorrect statements, which are frequently deduced from
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animal studies and therefore not completely transferable to
humans.
Any research on possible alterations of central 5-HT
neurotransmission (but also of other neurotransmitters) in
migraine subjects must consider a few, but definite clinical
remarks, which are evident to any headache specialist, as
the clear prevalence in females and familiarity. Among the
possible trigger factors, peri-menstrual period, the post-
stress weekend headache, the time immediately after an
intense emotion/alarm/fear, alcoholic drinks, are those
clearly associated with pain.
Peripheral studies
Platelets as a model of central 5-HT neurons, and then as
the mirror of possible alterations of 5-HT neurotransmis-
sion in the brain, concerning the content, receptors and
reuptake/transporter (SERT), were suggested and debated
in the literature. Plasma 5-HT and 5-HIAA are also mis-
leading since most plasma 5-HT is derived from the gut
and less than 10% of 5-HIAA comes from the brain.
Although no correlation was reported between midbrain
and platelet SERT, recent single photon emission tomog-
raphy (SPECT) evidence shows gender differences; that is
SERT in midbrain are positively correlated with 5-HT
uptake and negatively with 5-HT concentration of platelets,
but only in females [9]. An hypothetical alteration of brain
5-HT neurotransmission in migraine patients, probably
genetically determined, was repeatedly searched in the
periphery (platelets, vessels, etc.), and sex and seasons
were underlined as critical variables in the interpretation of
diagnostic group differences [1, 10].
Platelets
Generally, it was stated that migraine patients have low
platelet 5-HT, a sign of hyposerotonergic status of
migraine. However, the vast majority of data show normal
platelet and plasma 5-HT concentrations in migraine
without aura both between attack and during pain in
comparison with control subjects [11–25] (Table 1). Even
the number of platelet 5-HT transporters (indirect indices
of 5-HT reuptake) was normal in migraine and in chronic
tension headache [26]. The release of 5-HT from platelet
reported in some studies was probably non-specific and
was considered not casually related to migraine attack [10,
27]. The finding of higher 5-HT platelet content in
migraine with aura [18] was not confirmed [15, 21, 23].
Even in tension headache, platelet and plasma 5-HT are not
decreased in headache-free period in comparison to control
subjects [12–15, 19, 21, 28–34] (Table 2). Therefore, we
can state that a hyposerotonergic status is not present in
migraine and tension headache patients in the periphery.
The observed reduced platelet 5-HT in chronic migraine
with or without medication overuse [20, 35, 36] are not
found in chronic tension headache [34].
Vascular 5-HT reactivity
The larger amount of studies on 5-HT vascular reactivity in
migraine patients were performed in hand vein and
Table 1 Comparative studies of platelet/plasma 5-HT levels between
patients with migraine without aura in attack (In) and in attack-free
period (Out) and control subjects
References Platelets Plasma




Anthony [14] = =
Ferrari [15] = \ \ =
Nakano [16] =
D’Andrea [17] =
D’Andrea [18] = =
Kitano [19] =
Srikiatkhachorn [20] =
Stronks [21] = =
Evers [22] \ \ = =
Jerney [23] = =
Juhasz [24] \
Drummond [25] =
Table 2 Comparative studies of platelet/plasma 5-HT levels between
tension headache in attack (In) and in attack-free period (Out) with
control subjects
References Platelets Plasma









Jensen [31] = [
D’Andrea [32] [ [
Mazzotta [33] [
Bendtsen [34] = =
Stronks [21] = =
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previously reviewed [1]. From these studies three impor-
tant findings deserve discussion: in fact they can be related
to a possible 5-HT hypersensitivity provoked by hypose-
rotonergic state.
Gender differences
The evaluation of 5-HT reactivity in hand vein in a large
sample shows that migraine subjects are more sensitive to
controls. Moreover, female migraineurs are more sensitive
than male migraineurs (Fig. 1). Higher 5-HT sensitivity in
females was also found in other human vascular districts
such as mammary and radial arteries [38, 39]. Interestingly,
a heritable sexual dimorphism was described for whole
blood 5-HT levels with higher level in women compared
with men [40].
Important gender differences exist also in human brain
5-HT neurotransmission [41, 42], different to those with
animal studies [43]. Studies of cerebrospinal fluid (CSF)
concentrations of 5-HIAA, indirect indices of 5-HT syn-
thesis and, by implication, of the transmitter for release into
the synaptic cleft have yielded inconsistent results (see
[42]). However, 5-HIAA reflects other processes in addi-
tion to 5-HT synthesis.
Validated positron emission tomography (PET) studies
showed that men synthesize 5-HT significantly faster than
women, and also with left-to-right differences [42, 44]
even if an inverse finding was reported in a small study
[45]. These gender differences are found in cortical regions
but not in sub-cortical structures, including brainstem,
where most 5-HT cell bodies are found [42]. Acute tryp-
tophan depletion (ATP) causes a larger decrease in the rate
of 5-HT synthesis in women [44]. It was affirmed that
human males and females seem to have similar stores of
brain 5-HT, but if there were increased utilization of 5-HT
during stressful situations, a lower rate of synthesis in the
females may not be as efficient in maintaining adequate
stores of the neurotransmitter and then in such situations
the 5-HT level would decline more in females [44].
Healthy women were reported to have higher 5-HT trans-
porter availability in the diencephalon and brainstem
compared to men. Since the 5-HT transporter functions to
regulate 5-HT neurotransmission, these findings tend to
suggest that baseline 5-HT functions may be higher in
women versus men. Women have also higher number of 5-
HT1A receptors but not of 5-HT2A: the latter are, however,
increased by estrogens (see [41]). The greater (upregula-
tion) 5-HT1A bindings may be consequence of lower
activity (synthesis) of serotonergic system (see [42]).
Estrogens and estrogens + progesterone (that is the
reproduction of the hormonal cycle of females) act on the
gene and protein expression in dorsal raphe nucleus of non-
human primates in a manner that suggests that 5-HT neu-
rotransmission should increase: reduction of 5-HT1A,
decrease 5-HT reuptake transporter (SERT), increase of
tryptophan hydroxylase, MAO-A inhibition. The direct
evidence of steroid-induced 5-HT release was sought with
microdialysis [46].
Seasonal variation
The evaluation of seasonal changes in the vascular 5-HT
hand vein reactivity clearly shows a lesser 5-HT sensitivity
in the summer (Fig. 2). Many clinical studies, conducted in
Italy and Austria, show that migraine frequency is lower in
the summer in comparison to winter or autumn [47–52]
(Table 3). Other studies do not concord [49, 50]. However,
in one of these [50], when a bias was corrected, the sea-
sonal differences disappeared, and even if real the seasonal
effect is weaker. Also the reported higher attacks of
migraine with aura (but not without aura) in the light
season compared to the dark season in the arctic area
became insignificant when insomnia-related attacks were
removed [53]. In spite of this, in this latter study the peak
frequency of migraine without aura was in December and
the lowest frequency in June.
There are many evidences of increased content/turnover


















Fig. 1 5-HT reactivity in the hand vein expressed in venoconstriction
units (VCU). Significant differences were found in the 5-HT doses
eliciting roughly the same amount of contraction: migraine patients
(examined in headache-free period) are more sensible (lower 5-HT
dose) than controls (P \ 0.001), migraine women are more sensible
than migraine men (P \ 0.001). Data from Panconesi et al. [37]
Table 3 Frequency of migraine attack by seasons
References Winter Spring Summer Autumn
Marrelli [47] ++++ +++ + ++
Cugini [48] ++++ +
Robbins [49] + ++++ ++ +++
Fox [50] + ++ ++++ +++
Rieder [51] + ++++
Soriani [52] ++++ + ++++
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in the brain, and also of plasma and platelet 5-HT content
in the summer [1, 54].
The amount of 5-HT and its metabolites in the CSF are,
at best, an imprecise indicator of brain serotonergic neu-
ronal activity (synthesis). The measure of the differences
between concentrations of neurotransmitters in the arteries
and the internal jugular vein permit us to estimate the
amounts produced in the brain. With this technique it was
shown that in man, 5-HT turnover was lowest in winter and
highest in summer, and was correlated to the bright sun-
light of the day [55]. This finding was selective because
extracerebral 5-HT turnover and also brain turnover of
norepinephrine and dopamine did not show any seasonal
variation. Another interesting preliminary finding is the
reduced brain SERT availability in the winter compared to
the summer [56].
Habituation
About 25 years ago, it was proved that migraine patients
usually do not show tachyphylaxis (habituation) to the
vasoconstrictive activity of 5-HT, different to control
subjects [57].
Later on, the lack of habituation was thought to be the
principal interictal abnormality in sensory processing in
migraineurs, hypothesized due to hypofunction of 5-HT
pathway to the thalamus and cortex [58–62]. Normalization
of habituation during the attack was found [22, 63, 64] with
a parallel decrease of platelet 5-HT [22]. According
to Evers [22] the lack of significant association between
the amount of habituation and platelet or plasma 5-HT
suggested that the habituation phenomenon cannot be
attributed to 5-HT neurotransmission; however, central
5-HT modification cannot be excluded.
Although the phenomenon of reduced habituation in
migraineurs has been investigated mainly in the central
nervous system, there are examples even in the peripheral
system [65–67].
Central studies
Studies on the peripheral serotonergic system of migrai-
neurs were often inconsistent, partly because of negative
results, partly because of confounding factors, and their
significance remains a matter of debate [1, 10]. Attempts
toward an assessment of functional status of brain seroto-
nergic system in migraineurs in vivo have been, until
recently, possible only by the interpretation of mechanisms
of action of some serotonergic drugs followed by mea-
surement of their effects. There are few doubts that some
5-HT agonists can provoke a headache; what is in discussion
is their mechanism [6]. Three major classes of 5-HT agonists
exist: 5-HT releasing agents, 5-HT reuptake inhibitors
(SSRI), 5-HT receptor agonists. Recently, methods for
depletion of brain 5-HT and also neuroimaging studies to
assess brain 5-HT level in vivo were applied to migraine.
5-HT releasing agents
Reserpine and fenfluramine
A single dose of reserpine will consistently induce head-
aches, closely resembling migraine, when administered
intravenously, intramuscularly, or subcutaneously; but not
or rarely in healthy controls [68]. Also fenfluramine pro-
vokes headache in more than 50% of migraine patients,
with a mean latency of 4.5 h, which was suggested to be
due to 5-HT depletion, but not or less frequently in control
subjects [65, 69]. However, the hypothesized 5-HT neu-
ronal depletion as a mechanism of induced-headache
apparently contrasts with some reports showing that
chronic treatment with these two drugs, which probably
provokes more depletion than acute treatment, and with the
prototype of the depleting drugs p-chlorophenylalanine
(PCPA), can have therapeutic effect on some migraine
patients [69–71]. Fenfluramine challenge test administered
to healthy subject (no migraine sufferers), provoked side
effects in 90% of cases during the day, but more than half
the following day: headache/migraine account of 43% of
cases [72].
m-Chlorophenylpiperazine (mCPP)
The 5-HT2C receptor agonist mCPP is the most extensively
used probe to show an altered serotonergic neurotrans-
mission in migraine.
Brewerton et al. [73] reported that mCPP provoked
severe headaches with migraine features 6-12 h after a
single oral dose (0.5 mg/kg) in about 50% of female
subjects. The incidence of headache was significantly
greater in subjects with a personal or family history of







Winter (92) Spring (71) Summer (36) Autumn (62)
5HT (ng)
VCU
Fig. 2 Seasonal variations of 5-HT hand vein contraction, expressed
in venoconstriction units (VCU), in a group of 261 migraine patients.
In the summer higher 5-HT doses provoke a lesser amount of
venoconstriction. From Panconesi et al. [37], modified
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in female patients with bulimia nervosa than control,
irrespective of a personal or family history of migraine
[74]. Another study tested on a few subjects, predomi-
nantly men, reported that mCPP (0.25 mg/kg) induced
headache in 50% of subjects, but without differences
between migraine patients and controls, with a mean time
onset of 5.3 h [75]. The induction of migraine-like
headache in some subjects without personal history of
migraine was also reported during pharmacokinetics
studies, 5–10 h after oral administration [76]. However,
that mCPP provokes more migraine (according to Inter-
national Headache Society classification) than placebo
and more likely in migraine patients than in controls was
more recently confirmed [77].
The headache rating and duration was correlated with
plasma peak concentration of mCPP occurring several
hours earlier, and with the area under the curve (AUC),
without differences between migraine and controls [73–75,
77], but no relation with plasma level was also reported
[76]. Large inter-individual differences in mCPP pharma-
cokinetic parameters were shown [76, 78]. Interestingly,
the AUC after oral administration varied more than 40-
fold, was threefold higher than intravenous administration,
reached their peak after more than 3 h, and could still be
measured after 8 h, and no differences were seen between
male and females [76].
The fact that there were no differences in the cortisol
response to mCPP between migraine patients and controls
had led to the suggestion that 5-HT2C receptors are nor-
mal in migraine [75, 79]. Prolactin response was shown to
be both normal [75] and increased [79]. The peak of these
neuroendocrine responses was at 90–150 min, and both
correlation [75, 79], and non-correlation [78] with mCPP
plasma concentrations were reported. Also some sub-
jective side effects, other than headache, occur within 3 h
[78]. The fact that hormonal response precedes the
headache suggests that mCPP interaction with 5-HT
receptors in the brain occurs initially in the cascade of
events that ultimately results in headache [75], or that
headache is not due to direct 5-HT receptor stimulation.
Moreover, whether 5-HT receptor sensitivity is decreased
or increased probably depends on the anatomical location
of the pathway mediating the target response, and dif-
ferential involvement of 5-HT receptor subtype. In fact,
mCPP in addition to its 5-HT receptoral agonist activity is
similar to fenfluramine, a potent 5-HT releaser [80]. This
property should be taken into account for the similar time
latency in the headache provocation shown by these two
drugs.
However, for its adverse side effects and its variability
of pharmacokinetic and of clinical and hormonal effects,
m-CCP was suggested to be an inadequate drug to carry out
challenge tests to test receptor sensitivity in vivo [78].
Other 5-HT releasing drugs
The 3,4-methylenedioxymethamphetamine (MDMA/ecstasy)
is an illicit drug that stimulates the release of 5-HT from
neurons [80]. Although systematic studies have not been
performed to show headache provocation, a comprehensive
review of studies on the acute subjective effects of
MDMA shows that not only headache, but also nausea and
vomiting, is one of the more frequently reported somatic
effects [81].
Selective serotonin reuptake inhibitors (SSRI)
Two good reviews show that SSRI have no therapeutic
activity in migraine and tension headache [82, 83]. More-
over, the preventive effect of amitriptiline seems not due to
5-HT reuptake inhibition [84]. On the other hand, the
headache is not a main side effect of SSRI reported in the
headache treatment studies [6, 82]. Consequently 5-HT
reuptake inhibition, differently by 5-HT release or 5-HT
receptor agonism, seems not to be important in the path-
ogenesis of headache. What is the reason?
The SSRI and 5-HT releasers both elevate extracellular
concentration of transmitter via transporter-dependent
mechanism, but with important differences (see [80]):
(1) SSRI tends to produce small increases in extracellular
neurotransmitter whereas releasers tend to produce robust
increases as shown by in vivo microdialysis (2) Fenflura-
mine, norfenfluramine, mCPP and MDMA are potent 5-HT
releasers via carried-mediated exchange mechanism
involving SERT sites in the brain, (3) Fenfluramine and
mCPP also have direct agonist actions at 5-HT receptors.
Fenfluramine, especially their metabolite norfenfluramine,
are potent 5-HT2C and 5-HT2B receptor agonists, while
mCPP is a very potent agonist in human 5-HT2C receptors
and also at 5-HT1A [85]. One approach for discriminating
presynaptic (i.e., 5-HT release) versus postsynaptic (i.e., 5-
HT receptor agonism) activities is pretreatment with SSRI
which antagonize SERT and then the presynaptic effect of
5-HT releasers. Using this paradigm it was shown that
anorectic action of fenfluramine is mediated at least in part
by postsynaptic action. In this light, it would be of interest
to see if mCPP is capable of provoking headache during
SSRI treatment.
Another interesting finding was that high-doses of
mCPP do not deplete 5-HT in the brain, and therapeutic
doses of fenfluramine seem not to provoke depletion and
then neurotoxicity [80].
5-HT depletion
Historically, methods to functionally deplete serotonin
have been problematic and inapplicable to humans. Rapid
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tryptophan depletion (RTD) is a method that markedly
diminishes plasma tryptophan and brain 5-HT synthesis
and availability [44, 86], although there is evidence that it
does not alter the efflux/release from neurons [87]. RTD as
a method for studying 5-HT depletion is particularly suit-
able for subpopulations that show a vulnerability to 5-HT
dysregulation. That is, those groups that show a reduced
availability of central 5-HT are especially sensitive to RTD
[87, 88]. It was shown that RTD does not trigger full-blown
migraine attack, even if it intensifies migrainous symptoms
[25, 89].
Neuroimaging studies
Recently, neuroimaging studies demonstrated a significant
increase of mesopontine brainstem (but not in the thalamus,
the rostral relay station for nociceptive signals) SERT
availability in headache-free migraine patients, a site which
neuroimaging studies pointed to be specific for migraine
pathophysiology. However, it remains to be elucidated as
to whether it is causally related to migraine pathophysiol-
ogy, or whether it reflects a chronic pain condition, that is,
if it is the cause, or the consequence of migraine chroni-
fication [90]. Imaging methods to assess brain 5-HT level
in vivo are lacking; however, a PET study on a small group
of female migraine patients reported a global, non-region-
specific increase in the brain 5-HT synthesis capacity than
female controls [91].
Different from this study, it was shown recently that in
migraine patients the 5-HT synthetic rate was slightly
reduced with a sudden increase early in the attack, espe-
cially in the dorsal brainstem, to levels of control subjects:
sumatriptan promptly reduced the 5-HT synthesis to lower
values than those measured interictally, independently from
changes in pain intensity. No side effects appeared at any
stage. No differences were found between controls and
migraine subjects during the attack or interictally, even in
the last case, a slightly non significant reduction was found
[92]. The same study group shows that female migraine
patients exhibit lower 5-HT synthesis than female controls
[93]. As reported above, the reduced habituation of cortical
auditory and visually evoked potential in migraineurs in-
terictally is considered the most characterizing marker of
migraine patients, hypothesized due to a reduced preacti-
vation level of sensory cortices due to low 5-HT
neurostransmission [58–62]. These PET findings support
this interpretation, that is 5-HT availability is decreased in
the raphe-cortical serotonergic pathway. Also the normali-
zation of habituation deficit just before and during the attack
is in agreement with the increase of brain 5-HT synthetic
rate, and especially in the dorsal brainstem during attack.
However, from the numerous studies focused on genetic
alteration of 5-HT gene in migraine, there is no clear
evidence for 5-HT transporter polymorphisms associated
with migraine without aura [7, 8].
Conclusions
Numerous studies on platelet/plasma levels of 5-HT, as a
mirror of synapse of central 5-HT neurons, have led, in the
greater number of cases, to findings not showing a hypo-
serotonergic status in migraine and tension headache [1].
However, since most plasma/platelet 5-HT derive from the
gut, it is unlikely an index of brain 5-HT levels if there is
no particular genetic polymorphism of 5-HT metabolism
(concerning the reuptake, biosynthesis, receptors, etc.)
characterizing migraine subjects, so far not evidenced
[7, 8].
Some interesting aspects emerge from studies on 5-HT
vascular reactivity in migraine subjects: (1) an higher
sensibility, especially in women, in comparison to controls
(2) a reduced tachyphylaxis (habituation) successively
evidenced as the more characteristic abnormality of corti-
cal evoked potentials and ascribed to low 5-HT
neurotransmission, (3) a lesser 5-HT vascular reactivity in
the summer, when some studies show a lower incidence of
migraine. These peripheral findings could be in agreement
with a possible central hyposerotonergic status with con-
sequent postsynaptic receptoral supersensitivity, more
evident in women, and less in the summer.
The evidence of a possible alteration of brain 5-HT
neurotransmission was possible through the evaluation of
the effects of 5-HT agonists and of late with neuroimaging
studies. It was rather evident that 5-HT releasers provoke
headache both in migraine and controls, even if migraine
patients are generally more vulnerable [6]. The possible
mechanisms of these drugs are mainly two in number: (1) a
neuronal and thereafter extraneuronal 5-HT depletion,
consequent to 5-HT massive neuronal release and synaptic
metabolization, of 5-HT descending pain inhibitory neu-
rons of the brainstem, as previously suggested [65], (2) a
direct (or indirect through 5-HT release) action on post-
synaptic receptors. The first mechanism clash with animal
evidences showing that mCPP and fenfluramine do not
deplete brain 5-HT [80], and that RTD which diminished
brain 5-HT synthesis does not provoke migraine attack [25,
89]. The last mechanism could explain the induction of
migraine attack only through pain facilitating descending
neurons which impact on trigeminal dorsal horn nocicep-
tive neurons. In fact, both descending inhibitory and
facilitatory effects of 5-HT on nociceptive transmission
system from the brainstem are described [94, 95]. On the
other hand, there is no direct anatomical connection
between 5-HT raphe neurons and meningeal blood vessels.
These neurons innervate cortical microvessels [96], which,
272 J Headache Pain (2008) 9:267–276
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however, are lacking of sensory innervation [97]. Neuro-
imaging studies show that sumatriptan given during
migraine attack reduces 5-HT synthetic brain activity,
independently from pain relief, suggesting both a central
action of triptans, and that this mechanism is not involved
in therapeutic activity [92].
Some well-known trigger factors have been shown to
provoke 5-HT release. Acute alcohol intake increases 5-HT
release in the animal brain and in the platelets, and also a
biphasic effect, that is an initial facilitation of 5-HT activity
followed by a decrease several hours later, was reported
[98, 99]. Estrogens increase 5-HT neurotransmission and
release (see [42]). Biochemical studies have clearly shown
that 5-HT is a stress-responsive system with increase in
5-HT turnover during both acute and longer term stress
[5, 100]. The observation that migraine appearing in the per-
imenstrual period, in the relaxation period after prolonged
stress (weekend headache), after acute stress (intense
emotion/fear), or several hours after alcohol intake, can
share a previous period characterized by increased 5-HT
neurotransmission/release, which mime the action of 5-HT
releaser drugs, is particularly intriguing.
Sicuteri’s 5-HT central theory stated that migraine pain
originates from an alteration, apparently functional in
nature, of the neuraxial pain transmission. Pain arises
without any stimulation of nociceptors, but result from an
automatism of the nociceptive system, due to a failure of
anti-nociceptive 5-HT system [3]. According to a sub-
sequent theory called ‘‘functional deafferentation’’ [101], it
was argued that migraine is a sub-cortical system failure of
sensory modulatory networks that resulted in an enhanced
delivery to the conscious level of normal neuronal signals
such that they are perceived as abnormal [102]. Imaging
studies pointed that brainstem being specific for migraine
pathophysiology [90] and that migraine is a disorder
associated of low central 5-HT disposition associated with
an increase in 5-HT release during attack [7, 92].
On the other hand, some observations are not in accor-
dance with a peripheral genesis of migraine pain
(neurogenic inflammation):
1) Intracranial dura is innervated by neurons that exhibit
properties characteristic of nociceptors in other tissues,
and sumatriptan has no inhibitory effect on the
discharge of dural nociceptors, either in the basal
condition or after sensitization with inflammatory
mediators. Also calcitonin gene-related peptides
(CGRP) have no effect on the discharge of dural
nociceptors [97]. Instead sumatriptan itself produced a
transient discharge of these neurons which might
underlie the initial worsening of headache [97, 103]
that has been reported after sumatriptan administration
and ergot derivatives [6]. In fact not only subcutaneous
sumatriptan, but also small intravenous doses of
sumatriptan (500 lg), or of ergotamine (50 lg),
increase or provoke transitory, but sometimes long-
lasting, headache [104–106]. Interestingly, ergotamine
(50 lg), given to two migraine patients with mild
headache provoked after 2–3 min, concomitantly with
the start of hand vein contraction, a strong increase of
headache and nausea which was still present after
30 min and subsided after intramuscular diclofenac,
despite the persistence of a pronounced venoconstric-
tion (104). This initial worsening of headache was
suggested to be due to transitory high blood, and
perhaps cerebral, drug levels [6, 106].
2) The 5-HT1D receptors are equally distributed in cranial
afferents of the trigeminal system and in dorsal root
ganglion afferents, and then triptans should regulate not
only headache-associated pain, but also nociceptive
response in extracranial tissues; but this is not the case
[107].
3) Many 5-HT agonists, which potently inhibit neuro-
genic inflammation were ineffective in migraine
treatment [108].
Therefore, the original theory of migraine as a deficit of
central serotonergic antinociceptive system [3] is today
perhaps the more explicit, as maintained by other
researchers [7, 102].
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